Invenomic Capital Management
- Company typePrivate
- Founded2017
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Invenomic Capital Management firmographics
Firmographics- Name
- Invenomic Capital Management
- Legal name
- Invenomic Capital Management, LP
- Website
- https://invenomic.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Invenomic Capital Management industry classification
Industry- Product category
- Long/Short Equity Mutual Fund
- NAICS
- Open-End Investment Funds (525910), Open-End Investment Funds (52591)
- SIC
- Investment Advice (6282)
- akta.pro industry
- Equity Mutual Funds (Active)
Keywords
Where Invenomic Capital Management is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Invenomic Capital Management business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Investment Management Fees: The fund charges management fees through tiered expense ratios for different share classes: Institutional Class (2.23% net), Investor Class (2.48% net), Super Institutional Class (1.98% net). Redemption fee of 1.00% on shares sold within 60 days. Gross expense ratios range from 2.82% to 3.32% depending on share class.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Institutional Class shares with 2.23% net expense ratio |
| Subscription | Annual | Investor Class shares with 2.48% net expense ratio |
| Subscription | Annual | Super Institutional Class shares with 1.98% net expense ratio |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Invenomic Capital Management product offering
Product offeringCore offering
Invenomic Capital Management manages The Invenomic Fund, a long/short equity mutual fund that invests primarily in U.S. equities using a hybrid process combining quantitative idea sourcing with traditional fundamental analysis. The fund is offered in three share classes (Institutional, Investor, Super Institutional) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is distributed by Northern Lights Distributors, LLC to U.S. institutional and high-net-worth investors.
Product overview
Invenomic Capital Management operates as a single unified investment product: The Invenomic Fund. The fund is a long/short equity strategy that combines quantitative analysis on the front end to source ideas with traditional fundamental analysis to construct a portfolio of long and short equity positions. The fund offers three share class variants (Institutional Class, Investor Class, and Super Institutional Class) that differ primarily in fee structures and minimum investment requirements, with fund inception dated June 19, 2017.
Differentiator
Problem solved
Functional benefit
Products and services
- The Invenomic Fund A long/short equity mutual fund that employs a disciplined, fundamentally-driven research process to build a diversified portfolio of primarily U.S. focused long and short equity investments. The fund is offered in three share classes (Institutional BIVSX, Investor BIVRX, and Super Institutional BIVIX) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is managed by Portfolio Manager Ali Motamed for U.S. institutional and accredited/high-net-worth investors.
Quantifiable outcome
- Long portfolio typically 90%+ invested during most market environments
- +1 more outcomes
Companies that use Invenomic Capital Management
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Invenomic Capital Management technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Invenomic Capital Management partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Northern Lights Distributors, LLCcoreNorthern Lights Distributors, LLC is the fund distributor for The Invenomic Fund. They are a FINRA member broker-dealer (member FINRA/SIPC) responsible for distributing the fund shares to investors in the United States.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Invenomic Capital Management competitors and assessment
Company assessmentDirect peers
- HighVista Strategies: Boston-based alternatives manager running marketable securities portfolios. Brendan Dougherty worked in operations there prior to Invenomic, and the firm represents a similar-sized Boston alternatives boutique.
- Boston Partners: Long/short equity manager where Invenomic's founder Ali Motamed previously co-ran the Long/Short Equity Fund. Direct comparable on strategy, U.S. focus, and institutional client base.
- Hussman Strategic Advisors: Hedged U.S. equity mutual fund manager emphasizing risk management and downside protection. Directly comparable on mutual-fund distribution of a hedged U.S. equity strategy for retail and institutional investors.
- Balter Liquid Alternatives: Long/short equity mutual fund manager with a U.S. focus, founded by Nazar Massouh. Multiple Invenomic executives (President Ben Deschaine, Head of Client Relationships Bob Marx, and Client Relationship Kevin Ross) came directly from Balter, making it the closest comparable in product, channel, and talent pedigree.
- Bogle Investment Management: Quantitative, fundamentally-driven U.S. equity manager operating a small-cap value strategy. Brendan Dougherty (Invenomic's Director of Operations) spent over a decade at Bogle, making it a close operational and stylistic peer.
- The Merger Fund (Mercer Advisors): Long-running, mutual-fund-structured alternative strategy focused on event-driven U.S. equity. Comparable on offering a hedge-fund-style strategy through a U.S. mutual fund wrapper to retail and institutional clients.
- ValueAct Capital: Activist-leaning, fundamentally-driven U.S. long/short equity manager. Comparable on the focus on financial statement analysis, U.S. mandate, and concentrated fundamental research process.
Broad incumbents
- Gabelli Funds (Mario Gabelli): Long-running, fundamental-driven U.S. equity manager with mutual fund and institutional offerings. Comparable on long-only and hedged U.S. equity mutual fund distribution and fundamental research approach.
- AQR Capital Management: Large, established quantitative asset manager with a flagship long/short equity fund. Competitor for institutional long/short equity mandates at scale, with a much broader product suite and deeper quant research infrastructure.
- Calamos Investments: Established alternatives manager with multiple long/short and market-neutral mutual fund products. Competes for the same U.S. mutual fund-distributed long/short equity allocator.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Invenomic Capital Management social profiles
Digital presenceInvenomic Capital Management financial estimates
Financial estimateRevenue estimate
Valuation estimate
Invenomic Capital Management leadership team
Management profileNumber of profiles
Profiles7 records
Invenomic Capital Management funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Invenomic Capital Management M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Invenomic Capital Management
What does Invenomic Capital Management do?
Invenomic Capital Management manages The Invenomic Fund, a long/short equity mutual fund that invests primarily in U.S. equities using a hybrid process combining quantitative idea sourcing with traditional fundamental analysis. The fund is offered in three share classes (Institutional, Investor, Super Institutional) with tiered net expense ratios between 1.98% and 2.48% and a 1.00% redemption fee on shares sold within 60 days, and is distributed by Northern Lights Distributors, LLC to U.S. institutional and high-net-worth investors.
Is Invenomic Capital Management a public or private company?
Invenomic Capital Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Invenomic Capital Management founded?
Invenomic Capital Management was founded in 2017. It employs 11 to 50 people.
Where is Invenomic Capital Management based?
Invenomic Capital Management is headquartered in Boston, United States, in the North America region.
How does Invenomic Capital Management make money?
One revenue line is on record: investment Management Fees.
Who are Invenomic Capital Management's main competitors?
Direct peers on record are HighVista Strategies, Boston Partners, Hussman Strategic Advisors, Balter Liquid Alternatives, Bogle Investment Management, The Merger Fund (Mercer Advisors) and ValueAct Capital. Broad incumbents are Gabelli Funds (Mario Gabelli), AQR Capital Management and Calamos Investments.
Does Invenomic Capital Management have an API?
No public API is recorded for Invenomic Capital Management.
What industry is Invenomic Capital Management in?
Invenomic Capital Management's product category is Long/Short Equity Mutual Fund. Its primary akta.pro industry code is FSAAAEAA, Equity Mutual Funds (Active). Its NAICS code is 525910 and its SIC code is 6282.